Johnson & Johnson has faced nearly 2,000 Elmiron lawsuits in recent years, alleging that the interstitial cystitis drug caused vision problems, blindness.
A series of deadlines have been set to prepare the first bellwether Elmiron eye damage lawsuit for trial by late March 2023.
Trial was originally expected to begin in January 2023, for an Elmiron vision loss lawsuit filed by Maria Windham, who developed pigmentary changes and retina damage following use of Elmiron
The case is the first of three Elmiron bellwether lawsuits scheduled to go to trial in the first half of 2023.
Elmiron lawsuits over vision problems continue to be brought in state and federal courts nationwide, and it is ultimately expected that several thousand cases will be included in the litigation
Elmiron manufacturers failed to warn patients and doctors about the risk of retinal pigmentary changes linked to the bladder pain drug, the lawsuit alleges
Jury will consider evidence in January 2023, involving claims brought by a woman who experienced eye problems from Elmiron after just two years of use.
After preparing a group of 20 Elmiron lawsuits for trial as bellwether test cases, the Court has identified three claims that will go before juries in January, March and May 2023
Side effects of Elmiron caused vision loss, pigmentary changes and other eye damage that could have been avoided if the drug maker had provided proper warnings and instructions for users and the medical community.
Judge presiding over the litigation has ordered lawyers to submit information about each Elmiron vision loss claim that may be presented in advance of any settlement negotiations
